CORPORATION SCIENCE PARK TARAS SHEVCHENKO UNIVERSITY OF KYIV

Their core work

This organization is the commercial and research-transfer arm of Taras Shevchenko University of Kyiv — one of Ukraine's flagship research universities — structured as a science park to enable participation in EU-funded projects. Their scientific work sits at the intersection of nanomaterials chemistry and oncology: they develop nano-scale constructs capable of both imaging and treating cancer in a single platform (theranostics). Across their two H2020 projects, they have contributed expertise in synthesizing carbon-based nanomaterials and, more recently, ultra-small nanohybrids designed for bio-imaging and targeted cancer therapy. They operate as a research partner within MSCA-RISE staff exchange consortia, contributing laboratory know-how and researcher mobility to international collaborations.

What they specialise in

How they've shifted over time

In their first project (CARTHER, 2016–2019), the work was grounded in carbon-specific nanomaterials — a relatively defined material family — applied to theranostics without further published keyword differentiation. By their second project (UNAT, 2021–2026), the focus expanded toward ultra-small nanohybrids, a broader and more compositionally flexible class of materials, with explicit application targets in bio-imaging and cancer therapy named separately. The trajectory suggests a move from foundational carbon nanomaterial synthesis toward multicomponent hybrid systems designed for clinical translation, though both remain firmly within the nanomedicine theranostics space.

They are advancing from single-material carbon nanomaterials toward more complex nanohybrid architectures, which points to growing interest in multi-modal diagnostic and therapeutic platforms — a direction aligned with current preclinical nanomedicine research priorities.

How they like to work

This organization has never led an H2020 project — both participations are as a consortium partner within MSCA-RISE staff exchange programs, which are designed around researcher mobility rather than technical work-package leadership. With 8 unique partners across 5 countries over just two projects, their network is small and specialized rather than broad. This pattern suggests they are sought out for specific nanomaterials laboratory expertise and researcher exchange, not for project coordination or administrative leadership.

Their network spans 8 consortium partners across 5 countries, built entirely through MSCA-RISE exchanges — a mechanism that favors tight, recurring academic partnerships over broad industrial networks. Given their university affiliation, the majority of these partners are likely European research institutions with complementary nanoscience or oncology expertise.

What sets them apart

As the science park entity of Taras Shevchenko University — Ukraine's most prominent research university — they offer access to an established Eastern European academic nanomaterials research group with a proven track record of EU project compliance. Their consecutive participation in two MSCA-RISE theranostics consortia (2016 and 2021) demonstrates continuity and reliability as a partner in a niche where few Ukrainian organizations have built equivalent EU project history. For consortia seeking geographic diversity and deep nanomaterials chemistry expertise from a non-EU Eastern European partner, they fill a specific and difficult-to-replace slot.

Highlights from their portfolio

• UNAT
  The larger of the two projects (EUR 400,200, running to 2026), it represents a clear evolution in ambition — introducing ultra-small nanohybrids as a distinct platform with named bio-imaging and cancer therapy applications, suggesting growing methodological sophistication.
• CARTHER
  Their entry point into EU-funded nanomedicine research (2016), establishing foundational carbon nanomaterial expertise that directly seeded the follow-on UNAT project five years later.